Inspired and ambitious, our researchers are pioneers in cancer therapeutic development – focussed on developing our BRiDGECAR™ system, which combines our nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies.
If successful, we will be one step closer to our vision – targeted treatment for millions of cancer patients worldwide.
THE BRiDGECAR™ SYSTEM
BRiDGECAR™ has an advantage over competitors due to its dual functional capability:
- It has a direct targeting function via nfP2X7 derived antibody sequences, and
- It can attack cancer via additional BRiDGE antibodies, enhancing the cancer cell killing and minimising treatment resistance and patient relapse
BRiDGECAR™ incorporates industry leading advanced molecules that boost long-term cancer cell killing.
BRiDGECAR™ has the potential to treat most types of cancer.
BIOSCEPTRE’S BRiDGECAR™ DUAL-FUNCTIONALITY
The BRiDGECAR™ targets cancer both directly and via the BRiDGE™ antibodies.
BRiDGECAR™ T cells persist, hunting down and killing cancer cells between BRiDGE antibody treatments.
BRiDGECAR™ may provide ongoing tumour suppression via nfP2X7 after the administration of the BRiDGE antibodies has ceased.
Competitor approaches cannot do this.